Hjem › Nevroendokrin karsinom › Texas
Kliniske studier for Nevroendokrin karsinom i Texas
8 studier for Nevroendokrin karsinom søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- NEXT Dallas, Dallas
- START Dallas- Fort Worth, Dallas
- MD Anderson Cancer Center, Houston
- og 2 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07080242A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Austin
- Crinetics Study Site, Houston
- Crinetics Study Site, Irving
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- The University of Texas MD Anderson Cancer Center, Houston
- Oncology Consultants, PA- Houston, Houston
- Next Oncology Dallas, Irving
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT07174583A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 27. mai 2026 · NCT03093116A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2025 · NCT06943521Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.